Medidata Solutions Inc. (NASDAQ:MDSO) President Vries Glen Michael De sold 7,500 shares of the business’s stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $53.70, for a total value of $402,750.00. Following the completion of the sale, the president now directly owns 950,153 shares of the company’s stock, valued at $51,023,216.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vries Glen Michael De also recently made the following trade(s):

  • On Tuesday, August 9th, Vries Glen Michael De sold 7,500 shares of Medidata Solutions stock. The shares were sold at an average price of $54.39, for a total value of $407,925.00.
  • On Tuesday, July 12th, Vries Glen Michael De sold 32,500 shares of Medidata Solutions stock. The shares were sold at an average price of $49.25, for a total value of $1,600,625.00.

Shares of Medidata Solutions Inc. (NASDAQ:MDSO) opened at 55.37 on Tuesday. The firm has a market capitalization of $3.08 billion, a P/E ratio of 142.34 and a beta of 1.21. Medidata Solutions Inc. has a 52-week low of $30.22 and a 52-week high of $56.27. The firm has a 50-day moving average price of $54.17 and a 200-day moving average price of $46.15.

Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Wednesday, July 20th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Medidata Solutions had a net margin of 5.29% and a return on equity of 10.32%. The business earned $114.60 million during the quarter, compared to analysts’ expectations of $112.39 million. During the same quarter last year, the company earned $0.22 earnings per share. The firm’s revenue was up 16.8% on a year-over-year basis. On average, equities research analysts anticipate that Medidata Solutions Inc. will post $1.01 EPS for the current year.

Several large investors have recently added to or reduced their stakes in MDSO. FMR LLC boosted its stake in Medidata Solutions by 15.2% in the second quarter. FMR LLC now owns 6,908,046 shares of the company’s stock valued at $323,780,000 after buying an additional 913,489 shares during the last quarter. Vanguard Group Inc. raised its position in Medidata Solutions by 4.7% in the second quarter. Vanguard Group Inc. now owns 4,435,841 shares of the company’s stock valued at $207,909,000 after buying an additional 200,142 shares during the period. BlackRock Fund Advisors raised its position in Medidata Solutions by 3.1% in the second quarter. BlackRock Fund Advisors now owns 3,607,217 shares of the company’s stock valued at $169,070,000 after buying an additional 109,795 shares during the period. Champlain Investment Partners LLC raised its position in Medidata Solutions by 8.4% in the second quarter. Champlain Investment Partners LLC now owns 1,530,610 shares of the company’s stock valued at $71,740,000 after buying an additional 118,150 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in Medidata Solutions by 2.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,387,163 shares of the company’s stock valued at $65,016,000 after buying an additional 27,799 shares during the period.

Several analysts recently weighed in on the company. KeyCorp reissued a “buy” rating on shares of Medidata Solutions in a report on Thursday, July 7th. Morgan Stanley reaffirmed a “buy” rating on shares of Medidata Solutions in a report on Friday, June 10th. Zacks Investment Research lowered Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Needham & Company LLC began coverage on Medidata Solutions in a report on Monday, July 11th. They set a “buy” rating and a $55.00 target price for the company. Finally, Wells Fargo & Co. lowered Medidata Solutions from an “outperform” rating to a “market perform” rating in a report on Thursday, July 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $54.09.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.

5 Day Chart for NASDAQ:MDSO

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.